TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Universal Medication Schedule to Promote Adherence to Complex Drug Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 50+~* English or Spanish speaking~* Prescribed 3+ medications~* Primarily responsible for administering own medication~* Owns a cell phone and feels comfortable receiving texts~* Access and proficient in using internet at home and has a personal email address~Exclusion Criteria:~* Major cognitive, visual, or hearing impairment~* Doesn't meet inclusion criteria.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enhanced Usual Care (Type: NO_INTERVENTION): Patients who have not received the initial 6 weeks of text message reminders telling them to take their medicines; or did not complete at least 1 portal survey that asks them if they filled their medications, if they had any side effects or concerns; or did not receive either intervention will be considered as enhanced usual care.~Patients will only receive EHR tools (patient-friendly med-sheets about their medicines, MedList putting their medicines into the Universal Medication Schedule, and UMS sigs on their Rx bottles).
- Text or Portal (Type: ACTIVE_COMPARATOR): Participants who received EHR strategies as well as, the initial 6 weeks of SMS messaging continuously that remind them to take their medicines; or logged on to the patient portal and completed at least one survey will be considered as receiving the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women intolerable to oral iron. hbg \<10.9 g/dl during second or third trimester.~Exclusion Criteria:~* known sensitivity to IV iron. hemoglobinopathies. hemolytic anemia. women who have received or will receive blood transfusions. women with significant vaginal bleeding(\>200 cc blood loss)prior to delivery. women with documented history of allergy to more than one class of drug clinically significant anemia requiring therapy in the opinion of the obstetrician, in the first trimester.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- IV iron (Type: OTHER): Intravaneous iron(1000 mg low molecular weight iron dextran over 60 minutes) for moderate to severe iron deficient anemia of pregnancy in women intolerant of or unresponsive to oral iron.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who require continuous low-dose aspirin therapy during the treatment period with the study drug~2. Participants who have completed the preceding study~3. Outpatient (including inpatient for examinations)~Exclusion Criteria:~1. Participants deemed to be ineligible to participate in the study by the principal investigator or investigator due to the occurrence of adverse events in the preceding study~2. Participants who are scheduled to change the type and dosage regimen of low-dose aspirin~3. Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed during the preceding study~4. Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology~5. Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery~6. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders~7. Participants with a previous or current history of aspirin-induced asthma

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-438 10 mg QD (Type: EXPERIMENTAL): None
- TAK-438 20 mg QD (Type: EXPERIMENTAL): None
- AG-1749 15 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy people aged 3 years and above;~* I (or/and his/her legal guardian/authorized representative) can comply with the requirements of the clinical trial protocol after informed consent and voluntary signed informed consent;~* No contraindications of quadrivalent influenza vaccine in the package insert and meet the vaccination requirements after medical history inquiry.~Exclusion Criteria:~* Allergy to any component of the quadrivalent influenza vaccine, including egg, excipients, formaldehyde, or Triton X-100;~* people with a history of anaphylaxis after vaccination (allergy to any previous vaccination);~* Acute disease, severe chronic disease, acute onset of chronic disease, cold and fever;~* Axillary body temperature ≥37.3℃ (\> 14 years old) and ≥37.5℃ (≤14 years old) before vaccination;~* Uncontrolled epilepsy;~* patients with progressive neurological disease or a history of Guillain-Barre syndrome;~* receiving immunoglobulin injection for less than one month;~* vaccination with live attenuated vaccine within 14 days before and other vaccines within 7 days before vaccination;

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Approval consistency study (Type: None): A total of 1050 recipients aged 18-59 years were enrolled in this study. Blood samples were collected before and 30 days after vaccination. Hemagglutination inhibition (HI) antibody to influenza virus was detected in the serum of all recipients to evaluate the inter-batch consistency of the vaccine.
- Safety and immunogenicity in a larger vaccination cohort aged 3 years and older (Type: None): 3850 recipients were enrolled in an open trial: safety observation after vaccination, follow-up for adverse events (AE) 30 minutes and 0-30 days after vaccination, and SAEs for 6 months after vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Support for Perinatal Adherence and Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently pregnant~* HIV-infected and diagnosed with HIV during the index pregnancy~* Meet criteria for a major depressive episode~* Currently on antiretroviral therapy~* Receiving antenatal care at PMMH Gateway clinic~* Primary language English or isiZulu~* Access to a phone and willing to give researchers permission to reach them via phone~* Resident of Umlazi~Exclusion Criteria:~* Unable or unwilling to provide informed consent~* Active untreated, major mental illness (untreated psychosis, bipolar disorder, dementia, or active suicidality) that would interfere with study participation~* Less than 18 years of age

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Intervention: INSPireD (Type: EXPERIMENTAL): This 5-8 session group intervention, Integrating Nuanced Support for Perinatal adherence and Depression, aimed to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women. Intervention content was based on two established cognitive-behavioral interventions: problem-solving therapy and Cognitive Behavioral Therapy for Adherence and Depression.
- Treatment-as-usual + abbreviated intervention (Type: OTHER): This group received treatment-as usual, plus the option of completing an abbreviated version of the intervention (one session of problem-solving related to adherence and mental health) at the conclusion of study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Individualized Analgesia After Adenotonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children with obstructive sleep apnea syndrome undergoing elective T\&A, ASA physical status I-II~Exclusion Criteria:~* developmental delay cardiac and craniofacial abnormalities ASA classification III or more body mass index more than the 95th percentile for age

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Individualized opioid analgesia (Type: OTHER): One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine.Scored every 10 minutes until CHEOPS\<=6 and Aldrete score\>9.
- conventional opioid analgesia (Type: OTHER): Another group: all received 25μg/kg morphine .Scored every 10 minutes until CHEOPS\<=6 and Aldrete score\>9.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent or assent~* Confirmed diagnosis of CF~* History of chronic infection with Pseudomonas aeruginosa~* Sputum culture positive for Pseudomonas aeruginosa at Screening~* FEV1 ≥ 25% of predicted value at Screening~Key Exclusion Criteria:~* FEV1 \<25% of predicted at Screening~* History of major complications of lung disease within 8 weeks prior to Screening~* Hemoptysis of ≥60 mL in a 24-hour period within 4 weeks prior to Screening~* History of positive culture for Burkholderia cepacia within 2 years prior to Screening~* History of pulmonary tuberculosis or non-tuberculous mycobacterial lung disease treated within 2 years prior to Screening or requiring treatment at the time of screening~* History of Allergic Broncho-Pulmonary Aspergillosis or any other condition requiring systemic steroids at a dose ≥ equivalent of 10 mg/day of prednisone within 3 months prior to Screening~* Presence of any clinically significant cardiac disease~* History of lung transplantation~* Daily, continuous oxygen supplementation or nighttime supplemental oxygen requirement of greater than 2 L/min~* Administration of any investigational products within 8 weeks prior to study Day 1~* Smoking tobacco or any substance within 6 months prior to screening or anticipated inability to refrain from smoking throughout the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arikayce™ (Type: EXPERIMENTAL): Arikayce™ is liposomal amikacin for inhalation
- TOBI® (Type: ACTIVE_COMPARATOR): TOBI® is tobramycin inhalation solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: My Diabetes Care: A Scalability and Usability Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus~* Age 18-75 years old~* Currently taking at least one medication for diabetes~* Patient at a participating clinic within Vanderbilt Medical Center or Brigham and Women's Hospital~* Able to speak and read in English or Spanish~* Reliable access to a smartphone or tablet with internet access~* Active patient web portal account (for example, My Health at Vanderbilt or Patient Gateway)~Exclusion Criteria:~* Have a medical condition that affects your memory or ability to think~* Have severe difficulty seeing or hearing~* Have a medical condition that makes it hard for people to understand what you are saying

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- My Diabetes Care (MDC) Mobile (Type: EXPERIMENTAL): Patients have access to a patient web portal embedded with the My Diabetes Care (MDC) intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quetiapine Fumarate Bipolar Maintenance Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* 18 years or older~* A diagnosis of Bipolar I Disorder~* Have a current manic, depressed or mixed episode~* Have had a manic, depressed or mixed episode during the last 26 weeks that was treated with quetiapine~* Female patients of childbearing potential must be using a reliable method of contraception~Exclusion Criteria:~* Pregnancy~* Substance or alcohol dependence at enrollment~* Unstable thyroid function~* Unstable Diabetes~* Unstable or inadequately treated medical illness e.g., angina pectoris and hypertension~* Use of an experimental drug within 30 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult, ≥18 years of age at the time of informed consent~* A new, valid prescription for XERMELO~* Initiating XERMELO for the treatment of carcinoid syndrome~* Able and willing to provide informed consent prior to participation in the study~Exclusion Criteria:~* Unable to understand and read English~* Unable to access the internet~* Prior exposure to XERMELO

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carcinoid Syndrome patients initiating Xermelo (Type: None): Patients with Carcinoid Syndrome who are initiating treatment with XERMELO.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has signed written informed consent after the scope and nature of the investigation was explained to them~* Has difficulty falling asleep, maintaining sleep or has early morning awakenings~Exclusion Criteria:~* Significant medical or psychiatric illness causing sleep disturbances~* Has a history of bipolar disorder or family (immediate family) of suicide~* Has sleep disorder such as sleep related breathing disorder, restless leg syndrome, narcolepsy~* Has significant other medical illness such as acute or chronic pain, heart, kidney or liver disease within the last year~* Currently diagnosed or meets the criteria for Major Depressive Disorder (MDD) or has been treated for MDD with the last 2 years~* Substance abuse, excessive use of alcohol (as determined by the physician) or drug addiction within the last year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Esmirtazapine 1.5 mg (Type: EXPERIMENTAL): Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
- Esmirtazapine 3.0 mg (Type: EXPERIMENTAL): Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
- Esmirtazapine 4.5 mg (Type: EXPERIMENTAL): Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to esmirtazapine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Nonvalvular AF (NVAF) verified by at least two ECGs in the last year separated by at least one week.~* Previous cerebral ischemic attack (stroke or TIA, \>30 days prior to randomization)~* Previous systemic embolism.~* Symptomatic congestive heart failure (CHF)~* Impaired left ventricular systolic function~* Diabetes mellitus~* Hypertension requiring anti-hypertensive treatment.~Exclusion Criteria:~* AF secondary to reversible disorders, eg hyperthyroidism, drugs and pulmonary embolism~* Known contraindication to VKA treatment~* Presence of a valvular heart disease, mechanical heart valves, active endocarditis, left ventricular aneurysm or thrombus, atrial myxoma or any condition other than AF requiring chronic anticoagulation treatment~* Conditions associated with increased risk of major bleeding for example: history of intracranial bleeding, history of bleeding gastrointestinal disorder or major surgical procedure or trauma two weeks prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD0837 450 mg
- 2 (Type: EXPERIMENTAL): AZD0837 200 mg
- 3 (Type: EXPERIMENTAL): AZD0837 300 mg
- 4 (Type: EXPERIMENTAL): AZD0837 150 mg
- 5 (Type: ACTIVE_COMPARATOR): Vitamin-K antagonist at INR 2-3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Metastatic or unresectable clear cell kidney cancer confirmed by biopsy~* Previous nephrectomy~* Maximum of 1 previous regimen for metastatic disease~* Ability to perform activities of daily living with minimal assistance~* Measurable disease~* Adequate bone marrow, liver and kidney function~* Give written informed consent prior to study entry~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Age \< 18 years~* Treatment with more than one previous regimen for metastatic disease~* Clinically significant cardiovascular disease~* Active brain metastases~* History of CNS disease~* Clinical history of coughing or vomiting blood.~* History of thromboembolic disease.~* PEG or G-tube are ineligible.~* Current use of full dose anticoagulants or thrombolytic agents~* Chronic daily treatment with aspirin or NSAIDS~* Any clinical evidence or history of a bleeding or clotting disorder~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OSI-774 & bevacizumab (Type: EXPERIMENTAL): OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female previously unvaccinated healthy children aged 6 to \<36 months.~Exclusion Criteria:~* Any known or suspected impairment of the immune system, any serious disease.~* Any subjects receiving licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study.~* Individuals who have had influenza vaccine or documented suspected influenza disease prior to day 1.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 36 Months
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete